Marshall Ken W. 4
4 · Aquestive Therapeutics, Inc. · Filed Mar 9, 2023
Insider Transaction Report
Form 4
Marshall Ken W.
SVP, Chief Commercial Officer
Transactions
- Award
Common Stock
[F1]2023-03-09+150,000→ 150,000 total
Holdings
- 1,445(indirect: By Trust)
Common Stock
Footnotes (1)
- [F1]The Common Stock is represented by restricted stock which will vest in three annual installments with 25% on the 1st installment, 25% on the 2nd installment and 50% on the 3rd installment.
Signature
/s/ Lori Braender, as Attorney-In-Fact|2023-03-09